Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (11669)	9/18/2018 12:15:38 PM
From: Miljenko Zuanic	Respond to of 12215

RE: MDGL I see no reason (s) why would GLMD go down on those VK2809 results (it is mechanism confirmation and data are very similar....), so one would expect recovery in MDGL share price???? Also, I would expect recovery in GLMD share price??? But, as always MARKER reactions is beyond my reach!!! PS: I do not have dry powder to take position in MDGL (I have some calls from when stock was at 230),..this is nice opportunity for anyone who follow NASH, IMO. Cheers

To: Miljenko Zuanic who wrote (11669)	9/18/2018 12:26:40 PM
From: tuck	Read Replies (3) \| Respond to of 12215

At the risk of insulting your intelligence/knowledge . . . as to point #3, the trial was fairly small n, so there is still risk of a safety signal in a larger trial. Having room to reduce dose is a good thing to have in these circumstances. The lack of difference in blood pressure is interesting, given MDGL's results on that metric. It was thought to be an indirect result of overall benefit, not a direct result. Given that what we can see of VKTX' data looks just as good as MDGL's in terms of overall benefit, why didn't we see that? Trial not long enough, most likely. I'd expect a longer trial with similar results to start showing a blood pressure decrease, and I'd even expect that with a dose reduction. They'll need biopsy data and longer treatment for their next trial, whatever they call it (P2b or P2/3), so they're still well behind MDGL, and current difference in MC still justified. I'm not up to speed on their cash position, but these are the circumstances under which a company typically raises money. Since they have a number of programs to fund, it wouldn't surprise me at all. Do they have a shelf in place? Alternatively, they could partner. I don't know if they've discussed their partnering strategy. Cheers, Tuck